Last reviewed · How we verify
Fluzone® High-Dose
At a glance
| Generic name | Fluzone® High-Dose |
|---|---|
| Also known as | High-dose influenza vaccine, high dose influenza vaccine |
| Sponsor | Duke University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine (PHASE1)
- Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluzone® High-Dose CI brief — competitive landscape report
- Fluzone® High-Dose updates RSS · CI watch RSS
- Duke University portfolio CI